Cargando…

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report

Individuals with obesity due to pathogenic heterozygous melanocortin 4 receptor (MC4R) mutations can be treated efficiently with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide. Here, we report the effect of 16 weeks of liraglutide 3 mg/day treatment in a woman with morbid obesit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iepsen, Eva W., Have, Christian T., Veedfald, Simon, Madsbad, Sten, Holst, Jens J., Grarup, Niels, Pedersen, Oluf, Brandslund, Ivan, Holm, Jens-Christian, Hansen, Torben, Torekov, Signe S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7659505/ https://www.ncbi.nlm.nih.gov/pubmed/33205056 http://dx.doi.org/10.1016/j.xcrm.2020.100006

Ejemplares similares

Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss
por: Iepsen, E W, et al.
Publicado: (2015)

Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet
por: Jensen, Simon Birk Kjær, et al.
Publicado: (2019)

Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial
por: Sandsdal, Rasmus M., et al.
Publicado: (2023)

CCK‐1 and CCK‐2 receptor agonism do not stimulate GLP‐1 and neurotensin secretion in the isolated perfused rat small intestine or GLP‐1 and PYY secretion in the rat colon
por: Modvig, Ida M., et al.
Publicado: (2020)

Proteomics reveals the effects of sustained weight loss on the human plasma proteome
por: Geyer, Philipp E, et al.
Publicado: (2016)

Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function
por: Kielgast, Urd, et al.
Publicado: (2011)

Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy
por: Kjeldsen, Sasha A.S., et al.
Publicado: (2023)

Habitual physical activity is associated with lower fasting and greater glucose-induced GLP-1 response in men
por: Janus, Charlotte, et al.
Publicado: (2019)

L-Cell Expression of Melanocortin-4-Receptor Is Marginal in Most of the Small Intestine in Mice and Humans and Direct Stimulation of Small Intestinal Melanocortin-4-Receptors in Mice and Rats Does Not Affect GLP-1 Secretion
por: Kuhre, Rune E., et al.
Publicado: (2021)

Rare Heterozygous Loss-of-Function Variants in the Human GLP-1 Receptor Are Not Associated With Cardiometabolic Phenotypes
por: Melchiorsen, Josefine U, et al.
Publicado: (2023)

Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass
por: Jonsson, Isabella, et al.
Publicado: (2021)

Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial
por: Andersen, Emil, et al.
Publicado: (2022)

Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor Agonists
por: Umapathysivam, Mahesh M, et al.
Publicado: (2023)

Obesity treatment effect in Danish children and adolescents carrying Melanocortin-4 Receptor mutations
por: Trier, Cæcilie, et al.
Publicado: (2020)

Primary weight loss failure after Roux-en-Y gastric bypass is characterized by impaired gut-hormone mediated regulation of food intake
por: Bojsen-Møller, Kirstine Nyvold, et al.
Publicado: (2023)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

Melanocortins, Melanocortin Receptors and Multiple Sclerosis
por: Lisak, Robert P., et al.
Publicado: (2017)

Fasting Plasma GLP-1 Is Associated With Overweight/Obesity and Cardiometabolic Risk Factors in Children and Adolescents
por: Stinson, Sara E, et al.
Publicado: (2021)

The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults
por: Nilsson, Malin, et al.
Publicado: (2019)

N‐terminal alterations turn the gut hormone GLP‐2 into an antagonist with gradual loss of GLP‐2 receptor selectivity towards more GLP‐1 receptor interaction
por: Gabe, Maria Buur Nordskov, et al.
Publicado: (2022)

Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice
por: Clemmensen, Christoffer, et al.
Publicado: (2015)

What is Diabetes Remission?
por: Holst, Jens J., et al.
Publicado: (2021)

Identification of novel LEPR mutations in Pakistani families with morbid childhood obesity
por: Niazi, Robina Khan, et al.
Publicado: (2018)

Patients With Long-QT Syndrome Caused by Impaired hERG-Encoded K(v)11.1 Potassium Channel Have Exaggerated Endocrine Pancreatic and Incretin Function Associated With Reactive Hypoglycemia
por: Hyltén-Cavallius, Louise, et al.
Publicado: (2017)

Postprandial Diabetic Glucose Tolerance Is Normalized by Gastric Bypass Feeding as Opposed to Gastric Feeding and Is Associated With Exaggerated GLP-1 Secretion: A case report
por: Dirksen, Carsten, et al.
Publicado: (2010)

The Multifaceted Melanocortin Receptors
por: Laiho, Linda, et al.
Publicado: (2022)

Sequencing reveals protective and pathogenic effects on development of diabetes of rare GLIS3 variants
por: Sun, Jihua, et al.
Publicado: (2019)

Acute effects of glucagon‐like peptide‐1, GLP‐1(9–36 amide), and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers
por: Bremholm, Lasse, et al.
Publicado: (2017)

Genome-wide association study of circulating levels of glucagon during an oral glucose tolerance test
por: Jonsson, Anna, et al.
Publicado: (2021)

The anorexic hormone Peptide YY(3–36) is rapidly metabolized to inactive Peptide YY(3–34) in vivo
por: Toräng, Signe, et al.
Publicado: (2015)

Observations on the Evolution of the Melanocortin Receptor Gene Family: Distinctive Features of the Melanocortin-2 Receptor
por: Dores, Robert M.
Publicado: (2013)

Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses
por: Engelbrechtsen, Line, et al.
Publicado: (2018)

Data for amino acid alignment of Japanese stingray melanocortin receptors with other gnathostome melanocortin receptor sequences, and the ligand selectivity of Japanese stingray melanocortin receptors
por: Takahashi, Akiyoshi, et al.
Publicado: (2016)

A randomized, double‐blind, crossover study of the effect of the fluoroquinolone moxifloxacin on glucose levels and insulin sensitivity in young men and women
por: Juhl, Christian R., et al.
Publicado: (2022)

Novel agonist and antagonist radioligands for the GLP‐2 receptor. Useful tools for studies of basic GLP‐2 receptor pharmacology
por: Gadgaard, Sarina, et al.
Publicado: (2022)

Increased oral sodium chloride intake in humans amplifies selectively postprandial GLP‐1 but not GIP, CCK, and gastrin in plasma
por: Asmar, Ali, et al.
Publicado: (2020)

The melanocortin receptors and their accessory proteins
por: Ramachandrappa, Shwetha, et al.
Publicado: (2013)

SAT032 Circulating Neprilysin Activity Is Increased In Type 2 Diabetes And Fatty Liver Disease, And Reduces Following Bariatric Surgery And Liraglutide Therapy
por: Sampson Kjeldsen, Sasha Alexandra, et al.
Publicado: (2023)

OR0302 Regulation Of Human Melanocortin-5 Receptor By Isoforms Of Melanocortin-2 Receptor Accessory Proteins
por: Jiang, Shanshan, et al.
Publicado: (2023)

Melanocortin Receptor Accessory Protein 2-Induced Adrenocorticotropic Hormone Response of Human Melanocortin 4 Receptor
por: Soletto, Lucia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o3c88400ncela4fho9sknlb3kv